Program
QLS5132
A development code. Also written as “QLS5132; Bevacizumab”, “QLS5132; Platinum; Bevacizumab” and “QLS5132; Olaparib; Bevacizumab”.
Its studies are mostly in Carcinoma, Ovarian Epithelial · Stomach Neoplasms, led by Qilu Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 33 open or running | phase 3since Oct 20, 2026 | Apr 10, 2025 | Apr 2027phase 2 · NCT07453394 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 10, 2025First study: phase 1 study in Advanced Solid TumorsFirst studyNCT06932094 · 256 planned · China
- Mar 1, 2026Phase 2 study in Stomach NeoplasmsNCT07453394 · 626 planned
- Oct 20, 2026Phase 3 study in Carcinoma, Ovarian EpithelialPhase 3 reachedNCT07926048 · 420 planned
Ahead
- Apr 2027Primary completion: phase 2 study in Stomach NeoplasmsNCT07453394
- May 2027Primary completion: phase 1 study in Advanced Solid TumorsNCT06932094
- Dec 2029Primary completion: phase 3 study in Carcinoma, Ovarian EpithelialNCT07926048
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07926048Carcinoma, Ovarian Epithelial | 3 | Not yet recruiting | Dec 2029 | 420 |
| NCT07453394Stomach Neoplasms | 2 | Not yet recruiting | Apr 2027 | 626 |
| NCT06932094Advanced Solid Tumors · China | 1 | Not yet recruiting | May 2027 | 256 |
How it is read
Names in the registry
- “QLS5132”, 2 entries
- “QLS5132; Bevacizumab”, 1 entry
- “QLS5132; Platinum; Bevacizumab”, 1 entry
- “QLS5132; Olaparib; Bevacizumab”, 1 entry
Codes read as this program: QLS5132.
Conditions, from the studies’ own filings
- Carcinoma, Ovarian Epithelial, 1 study
- Stomach Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.